U.S. Markets closed

Bristol-Myers Squibb Company (BMY)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
62.31+0.53 (+0.86%)
At close: 4:00PM EST

Bristol-Myers Squibb Company

430 East 29th Street
14th Floor
New York, NY 10016
United States
212 546 4000
http://www.bms.com

Sector(s)Healthcare
IndustryDrug Manufacturers—General
Full Time Employees30,000

Key Executives

NameTitlePayExercisedYear Born
Dr. Giovanni CaforioChairman & CEO6.22MN/A1965
Mr. David V. ElkinsExec. VP & CFO3.62MN/A1968
Ms. Sandra Leung Esq.Exec. VP & Gen. Counsel2.92M5.84M1961
Dr. Christopher S. BoernerExec. VP & Chief Commercialization Officer2.49MN/A1971
Mr. Rupert Vessey M.A.Exec. VP and Pres of Research & Early Devel.3.31MN/A1965
Mr. Paul von AutenriedExec. VP & Chief Information OfficerN/AN/A1962
Mr. Timothy PowerVP & Head of Investor RelationsN/AN/AN/A
Mr. Adam DubowSr. VP, Chief Compliance & Ethics OfficerN/AN/A1967
Ms. Ann M. Powell JudgeExec. VP & Chief HR OfficerN/AN/A1966
Mr. Louis S. SchmuklerExec. VP and Pres of Global Product Devel. & SupplyN/AN/A1956
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. The company's products include Opdivo for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia for adult patients with active RA and prostate-specific antigen, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, it offers Reyataz, a protease inhibitor to treat human immunodeficiency virus (HIV); Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. The company has collaboration agreements with Pfizer, Otsuka, Ono, Nektar, GRYT Health, Ubiquigent Limited, and Sensyne Health plc; clinical collaboration with NeoImmuneTech, Inc.; partnership with Astrazeneca Plc; a discovery collaboration with Insitro, Inc.; and collaboration with Schrödinger, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

Corporate Governance

Bristol-Myers Squibb Company’s ISS Governance QualityScore as of November 2, 2019 is 5. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 5; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.